Applied health economics and health policy
-
Appl Health Econ Health Policy · Sep 2012
ReviewPleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance.
The PleurX peritoneal drainage catheter for drainage of malignant ascites in a community setting has been evaluated by the NICE Medical Technologies Evaluation Programme. This article outlines the evidence included in the Sponsor's submission, the independent critique by the External Assessment Centre (EAC) and the recommendations made by the Medical Technologies Advisory Committee (MTAC). In accordance with the scope issued by NICE, the intervention technology was the indwelling PleurX peritoneal catheter drainage system, the comparator was large-volume paracentesis (LVP; inpatient or outpatient) and the population was patients with treatment-resistant, recurrent malignant ascites. ⋯ There was uncertainty surrounding the number of patients for whom insertion of a PleurX drain would be appropriate as well as the point in the care pathway at which such treatment should be administered. MTAC supported the case for adoption and considered that the available evidence showed PleurX was clinically effective, has low complication rates, can improve quality of life and is less costly than inpatient LVP. In Medical Technology Guidance 9 (MTG9), NICE recommended that PleurX peritoneal catheter drainage system be considered for use in patients with treatment-resistant, recurrent malignant ascites.
-
Appl Health Econ Health Policy · May 2012
Review Comparative StudyCost effectiveness of prostacyclins in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be driven by factors such as efficacy, administration route, safety profile and economic aspects. ⋯ Initiating prostacyclin treatment with iloprost in patients with PAH, functional class III of the NYHA, is the less costly alternative for the NHS in Spain, with a good efficacy profile when compared with the other alternatives.
-
Appl Health Econ Health Policy · May 2012
ReviewEconomic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts.
One of the challenges when undertaking economic evaluations of weight management interventions is to adequately assess future health impacts. Clinical trials commonly measure impacts using surrogate outcomes, such as reductions in body mass index, and investigators need to decide how these can best be used to predict future health effects. Since obesity is associated with an increased risk of numerous chronic diseases occurring at different future time points, modelling is needed for predictions. ⋯ This is the first literature review comparing methods used in economic evaluations of weight management interventions, and it is the first time that observed differences in study results are addressed with a view to methodological explanations. We conclude that many studies have methodological deficiencies and we urge analysts to follow recommended practices and use models capable of depicting long-term health consequences.
-
Appl Health Econ Health Policy · Jan 2010
ReviewA systematic data review of the cost of rehydration therapy.
Dehydration secondary to acute gastroenteritis is a commonly encountered condition among patients presenting to physicians' offices and hospital EDs. Treatment options consist of oral rehydration therapy (ORT), intravenous rehydration therapy (IVRT) and subcutaneous rehydration therapy (SCRT). Although most patients with dehydration can be effectively treated in an outpatient setting, hospitalization is frequently warranted, with estimated annual inpatient costs for dehydration therapy exceeding $US1 billion in the US in 1999 for elderly patients alone. ⋯ A total of 20 reports containing pharmacoeconomic data on rehydration therapy were evaluated. Findings suggest that ORT and SCRT may be less costly than IVRT in the treatment of mild to moderate dehydration; however, variability in cost parameters examined or data collection methods described in the literature precluded a comprehensive comparative cost-effectiveness analysis of treatment options. Future pharmacoeconomic analyses of rehydration therapy should incorporate time-motion analyses comprising a consistent set of variables to determine the most cost-effective treatment modality for patients with mild to moderate dehydration.
-
Appl Health Econ Health Policy · Jan 2002
ReviewWhat do we know about hospital at home? Lessons from international experience.
Hospital in the home' or 'hospital at home' services have become popular solutions to the apparent problems of conventional hospital care in many countries. Until recently their evaluation has been limited, and little has been known about their costs and benefits. ⋯ Overall it does not appear that such services produce cost savings, although this may depend greatly on local circumstances. This discussion paper uses the findings of a systematic review of the literature evaluating hospital at home and hospital in the home services to answer questions surrounding the supplementary or substitution status of these services.